TVA Medical has provided clinical updates involving its everlinQ endoAVF system at the 2017 Leipzig Interventional Course (LINC; 24–17 January, Leipzig, Germany).
Medtronic has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a study of the In.Pact Admiral drug-coated balloon for a potential new indication in patients with end-stage renal disease.
Gore has announced that the Gore Viabahn VBX balloon expandable endoprosthesis has received US FDA approval for treatment of de novo or restenotic lesions found in iliac arteries, including lesions at the aortic bifurcation.
Cardiovascular systems (CSI) presented six-month data from its LIBERTY 360 degrees post-market study in a presentation at the 29th International Symposium on Endovascular Therapy (ISET; 4-8 February, Hollywood, USA). The study is evaluating the acute and long-term clinical and economic outcomes of peripheral vascular interventions in treating patients with symptomatic lower extremity peripheral artery disease.
Argon has announced that it has completed the sale of its Critical Care Unit including a manufacturing facility in Yishun, Singapore and related commercial operations in Europe and Japan, to Merit.
While drug-eluting devices, be they balloons or stents, use chemotherapeutic agents (usually paclitaxel) to reduce the build-up of scar tissue inside the arteries, a microinfusion device that applies the anti-inflammatory agent, dexamethasone, to the outside of arteries to enhance healing, is seeing largescale early positive results.
Barry Katzen, Miami, USA, announced the establishment of a new society, the Critical Limb Ischaemia (CLI) Global Society, whose mission is to improve quality of life by preventing amputations and death due to the condition.
Scott Trerotola presented the first release of eight-month data from the Lutonix AV IDE trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany) and showed that drug-coated balloons (Lutonix 035 AV from Bard) are linked with a significantly higher target lesion patency and far fewer reinterventions to maintain this opening in a wide variety of failing arteriovenous fistulas than standard angioplasty.
Penumbra has announced the presentation of the results of the ASTER trial, the first independent, prospective, randomised trial comparing the use of Penumbra’s aspiration system to stent retriever, in the opening plenary session at the International Stroke Conference in Houston, Texas.
Cook Medical has rounded out the Universa line with the introduction of two new sets for percutaneous urinary drainage.
BTG has announced that US FDA 510(k) clearance has been granted to the Ekos control unit 4.0.
Mentice has announced the release of the world’s first simulation training software module for prostatic artery embolization. The software, created from real patients’ data, will allow interventional radiologists to train for the procedure.
Surefire, the developer of site-specific delivery devices for the interventional oncology market, has announced the first closing of a US$12.8 M Series D financing round.
Nobilis Health has closed its previously announced acquisition of Hamilton Vein Center.
The pivotal VeClose trial is investigating the performance of the VenaSeal cyanoacrylate-based adhesive (Medtronic) for vein closure. At LINC 2017, Vascular News caught up with Raghu Kolluri (OhioHealth Vascular Institute, Columbus, USA) who explained his experience with the system thus far and why he is excited about the trial’s “excellent” 24-month outcomes.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos